United States


UCB.BR on Brussels Stock Exchange

26 Jun 2017
Change (% chg)

€0.20 (+0.32%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for UCB.BR


UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia,... (more)


Beta: 0.86
Market Cap(Mil.): €12,061.30
Shares Outstanding(Mil.): 194.51
Dividend: 1.15
Yield (%): 1.30


  UCB.BR Industry Sector
P/E (TTM): 21.51 14.09 19.01
EPS (TTM): 2.88 -- --
ROI: 7.10 -6.73 -5.03
ROE: 9.65 -6.18 -4.28

Heart safety clouds hopes for Amgen, UCB bone drug approval

Amgen Inc and UCB SA no longer expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial.

May 23 2017

UPDATE 4-Heart safety clouds hopes for Amgen, UCB bone drug approval

* UCB shares drop 18 pct, Amgen shares down 2 pct (Adds Amgen, UCB, Radius Health share moves)

May 22 2017

BRIEF-UCB gets positive CHMP opinion for Cimzia electronic injection device

* Positive CHMP opinion for Cimzia electronic injection device

Apr 26 2017

BRIEF-UCB Q1 Cimzia sales up at 317 million euros

* Q1 immunology/Cimzia sales 317 million euros ($344 million) versus 281 million euros year ago

Apr 24 2017

BRIEF-UCB and Q-State enter into multi-yr therapeutics discovery collaboration

* And Q-state biosciences form research collaboration to develop novel therapeutics for genetic subtypes of epilepsy

Apr 04 2017

Ex-UCB executive loses bid to seal whistleblower lawsuit

A federal judge has denied a former UCB SA executive's request to keep a whistleblower lawsuit he filed against the drug company under seal, rejecting his argument that he may face retaliation from his new employer once his identity becomes public.

Mar 08 2017

BRIEF-UCB releases new CIMZIA data in moderate-to-severe plaque psoriasis

* Announced on Saturday that new Cimzia (Certolizumab Pegol) demonstrated statistically and clinically significant improvements for patients with moderate-to-severe chronic plaque psoriasis

Mar 06 2017

Pharma group UCB guides for further growth in 2017

BRUSSELS, Feb 23 Belgian pharmaceutical group UCB forecast on Thursday revenues and core profit would continue to grow in 2017 after sales of all of its key drugs were above analysts' expectations in 2016.

Feb 23 2017

BRIEF-UCB FY revenue, operating profit ahead of Reuters poll

* Reports FY revenue of 4.18 billion euros ($4.42 billion) versus 4.12 billion euros in Reuters poll

Feb 23 2017

BRIEF-UCB files Briviact CV in US as monotherapy treatment for adult epilepsy patients with partial-onset seizures

* UCB files Briviact (brivaracetam) CV in the US as monotherapy treatment for adult epilepsy patients with partial-onset seizures Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 19 2017

More From Around the Web

Earnings vs. Estimates